Fig. 3
The immune infiltrate of BrafV600E/Pten−/− tumors is altered with loss of Cxcr2. a mMCPCounter analysis performed on bulk RNAseq data from BrafV600E/Pten−/−melanoma tumors with or without Cxcr2 predicts significantly enhanced infiltration of T cells, CD8 + T cells, monocytes, NK cells, and lymphatic vessels into Cxcr2−/− tumors. b FACS analysis of CD45 + myeloid cells in BrafV600E/Pten−/− melanoma reveals decreased MDSC-like cells in Cxcr2−/− tumors. c FACS analysis of CD45 + cells in BrafV600E/Pten−/− melanoma tumors identified changes in activated CD4 + CD44 + T cells and CD8 + CD69 + T cells. d Cytokine array for 62 cytokines expressed in TME of BrafV600E/Pten−/− tumors revealed one major cytokine, CCL20, that is strongly upregulated with loss of Cxcr2 (n = 4/genotype) based on net density. These data are complemented by increased Ccl20 mRNA with loss of Cxcr2 in BrafV600E/Pten−/− tumors. e Cxcl9, Cxcl10, and PD-L1 expression based upon RNAseq analysis from BrafV600E/Pten−/− tumors expressing or not expressing Cxcr2 in melanocytes. All statistical significance determined via Welch’s t-test